InnoCan Pharma Corporation (CSE:INNO)
Canada · Delayed Price · Currency is CAD 2.440
+0.090 (3.83%)
Sep 17, 2026, 5:16 PM EST
InnoCan Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 23.53 | 26.61 | 29.44 | 13.66 | 2.56 | 0.2 | |
Revenue Growth | -18.39% | -9.60% | 115.55% | 433.69% | 1205.61% | 2350.00% |
Cost of Revenue | 2.25 | 2.68 | 3.25 | 1.68 | 0.45 | 0.08 |
Gross Profit | 21.28 | 23.93 | 26.19 | 11.98 | 2.11 | 0.12 |
Selling, General & Admin | 23.96 | 24.25 | 25.89 | 13.99 | 6.85 | 6.2 |
Research & Development | 0.75 | 0.93 | 1.55 | 1.8 | 1.53 | 1.4 |
Operating Expenses | 24.71 | 25.19 | 27.43 | 15.78 | 8.37 | 7.6 |
Operating Income | -3.43 | -1.26 | -1.25 | -3.8 | -6.27 | -7.48 |
Interest Expense | - | -0 | -0.01 | - | -0 | -0.01 |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | -0.04 | 0 | -0.42 | -0.29 |
Other Non Operating Income (Expenses) | 2.07 | 1.6 | 2.22 | -0.24 | 2.8 | -2.31 |
EBT Excluding Unusual Items | -1.27 | 0.38 | 0.92 | -4.03 | -3.89 | -10.09 |
Other Unusual Items | 0.4 | -0.29 | - | - | - | - |
Pretax Income | -0.88 | 0.09 | 0.92 | -4.03 | -3.89 | -10.09 |
Income Tax Expense | -0.04 | 0.43 | 1.18 | 0.21 | 0 | - |
Earnings From Continuing Operations | -0.83 | -0.34 | -0.26 | -4.25 | -3.89 | -10.09 |
Minority Interest in Earnings | -0.13 | -0.78 | -1.57 | -0.45 | 0.13 | 0.04 |
Net Income | -0.96 | -1.12 | -1.83 | -4.7 | -3.76 | -10.05 |
Net Income to Common | -0.96 | -1.12 | -1.83 | -4.7 | -3.76 | -10.05 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 3 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 3 |
Shares Change | 1.40% | 3.92% | 8.96% | 3.23% | 10.87% | 38.59% |
EPS (Basic) | -0.21 | -0.25 | -0.43 | -1.19 | -0.98 | -2.91 |
EPS (Diluted) | -0.21 | -0.25 | -0.43 | -1.19 | -0.98 | -2.91 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1.55 | 0.48 | -1.59 | -3.95 | -6.09 | -6.67 |
Free Cash Flow Per Share | -0.34 | 0.11 | -0.37 | -1.00 | -1.59 | -1.93 |
Gross Margin | 90.46% | 89.93% | 88.96% | 87.71% | 82.34% | 61.73% |
Operating Margin | -14.60% | -4.72% | -4.24% | -27.85% | -244.86% | -3816.33% |
Profit Margin | -4.08% | -4.22% | -6.23% | -34.41% | -147.09% | -5126.02% |
Free Cash Flow Margin | -6.58% | 1.80% | -5.42% | -28.92% | -238.10% | -3403.06% |
EBITDA | -3.4 | -1.21 | -1.21 | -3.77 | -6.23 | -7.44 |
EBITDA Margin | -14.44% | -4.56% | -4.12% | -27.61% | -243.49% | - |
D&A For EBITDA | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 |
EBIT | -3.43 | -1.26 | -1.25 | -3.8 | -6.27 | -7.48 |
EBIT Margin | -14.60% | -4.72% | -4.24% | -27.85% | -244.86% | - |
Effective Tax Rate | - | 501.18% | 128.51% | - | - | - |